Key result
Lower plasma adiponectin levels (≤ 3 μg/mL) were independently associated with a significantly higher risk of acute myocardial infarction in non-obese patients (OR 8.97).
Why the study?
Is lower plasma adiponectin associated with acute myocardial infarction in non-obese patients?
Case-Control (n=86)
No
Is lower plasma adiponectin associated with acute myocardial infarction in non-obese patients?
Odds Ratio: 8.97 (95% CI 2.3–34.5)
p-value: p=0.001
Lower plasma adiponectin levels are independently associated with acute myocardial infarction in non-obese patients, suggesting a potential role in atherosclerosis pathophysiology independent of obesity.
Should not change AMI risk assessment in non-obese patients; extends observational links but leaves causal role open.
BACKGROUND: Adiponectin is an adipose tissue-derived mediator with significant anti-atherogenic properties. A few studies were done in acute phase of myocardial infarction especially in non obese patients. We design a study to investigate the association between adiponectin concentration and acute phase of myocardial infarction in non obese patients. METHODS: This case-control study was done in Paymaneah Hospital (Jahrom, Iran) from Feb 2007 to May 2008. Plasma adiponectin levels were measured in 43 patients with AMI (mean age: 62.7 +/- 13.3 years, male: 67.4%) at the first 24 hours of admission and 43 normal controls (mean age: 62.1 +/- 12.3 years, male: 55.8%) matched for age, sex and other CAD risk factors. RESULTS: Adiponectin levels in patients with AMI (3.36 microg/mL) were significantly lower than that of the control group (5.03 microg/mL) (p < 0.0001). Lower adiponectin were independently associated with higher risk of AMI (odds ratio = 8.97; 95% CIs: 2.3-34.5; p = 0.001). Adiponectin levels negatively correlated with triglyceride (r = -0.46, p = 0.002) and total cholesterol (r = -0.32, p = 0.03) in the case group and with body mass index (BMI) in control subjects. CONCLUSION: The present study showed that adiponectin was associated with AMI in non obese patients but it is not related to sex, age and other CAD risk factors.
No takes yet. Share an insight, caveat, or question.
Shojaie et al. (2009) conducted a case-control in Acute myocardial infarction (n=86). Lower adiponectin levels (≤ 3 μg/mL) vs. Higher adiponectin levels (> 5 μg/mL) was evaluated on Acute myocardial infarction (OR 8.97, 95% CI 2.3-34.5, p=0.001). Lower plasma adiponectin levels (≤ 3 μg/mL) were independently associated with a significantly higher risk of acute myocardial infarction in non-obese patients (OR 8.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: